The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - Amgen; Biomarin
Consulting or Advisory Role - Aduro Biotech; Apex; Codexis; Corcept Therapeutics; Crown Bioscience; Exelixis; KaloBios; Nektar; NewGen Therapeutics; Numedii; Oxigene; Pharm-Olam; Prothena; Raptor Pharmaceuticals; Stealth Biotherapeutics; Upsher-Smith
Phase 1/2 study of glucocorticoid receptor (GR) antagonist mifepristone (MIFE) in combination with eribulin (E) in advanced solid tumors, with dose expansion in patients with GR-positive (GR+) triple-negative breast cancer (TNBC).
 
Sharon Wilks
No Relationships to Disclose
 
Manuel R. Modiano
No Relationships to Disclose
 
Alexander I. Spira
Honoraria - Novartis; Roche
Research Funding - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Clovis Oncology; MedImmune; Roche
Expert Testimony - Novartis
Travel, Accommodations, Expenses - Roche
 
Carlos Becerra
Consulting or Advisory Role - Novocure
Speakers' Bureau - Celgene; Lilly; Taiho Pharmaceutical
 
Hyo S. Han
No Relationships to Disclose
 
Fadi S. Braiteh
Employment - US Oncology
Honoraria - Ambry Genetics; Amgen; BIND Therapeutics; bioTheranostics; Caris Life Sciences; Foundation Medicine; Incyte; Insys Therapeutics; Ipsen; Lilly; Merrimack; MolecularHealth; Novartis; Novocure; Pfizer; Pfizer; Roche/Genentech; Sanofi
Consulting or Advisory Role - Ambry Genetics; Amgen; BIND Therapeutics; bioTheranostics; Caris Life Sciences; Foundation Medicine; Incyte; Insys Therapeutics; Ipsen; Lilly; Merrimack; MolecularHealth; Novartis; Novocure; Pfizer; Roche/Genentech; Sanofi
Speakers' Bureau - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Genomic Health; Incyte; Insys Therapeutics; Ipsen; Lilly; Merck; Merrimack; Pfizer; Sanofi
Research Funding - Ambry Genetics (Inst); Amgen (Inst); BIND Therapeutics (Inst); bioTheranostics (Inst); Caris Life Sciences (Inst); Foundation Medicine (Inst); Incyte (Inst); Insys Therapeutics (Inst); Ipsen (Inst); Lilly (Inst); merrimack (Inst); MolecularHealth (Inst); novartis (Inst); Novocure (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Ambry Genetics; amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Celgene; Foundation Medicine; Genomic Health; HERON; incyte; Insys Therapeutics; Ipsen; Lilly; Merrimack; MolecularHealth; novartis; Pfizer; Roche/Genentech; Sanofi
 
Elisavet Paplomata
Research Funding - Corcept Therapeutics; Genentech; Hoosier Cancer Research Network; Novartis
 
Timothy J. Pluard
Consulting or Advisory Role - Bayer/Onyx
Speakers' Bureau - Genentech/Roche; NanoString Technologies
 
Donald A. Richards
Consulting or Advisory Role - Boehringer Ingelheim; Insys Therapeutics; IntegraGen; Lilly; Pharmacyclics
Speakers' Bureau - Celgene
 
Joyce O'Shaughnessy
Consulting or Advisory Role - Corcept Therapeutics; Eisai
 
Jackie Walling
No Relationships to Disclose
 
Robert S. Fishman
Employment - Corcept Therapeutics
Leadership - Corcept Therapeutics
Stock and Other Ownership Interests - Corcept Therapeutics; InterMune
Consulting or Advisory Role - Emphasys Medical
Research Funding - Corcept Therapeutics; InterMune
 
Gabrielle Baker
No Relationships to Disclose
 
Suzanne D. Conzen
Consulting or Advisory Role - Hospira
Patents, Royalties, Other Intellectual Property - Corcept Therapeutics
 
Rita Nanda
No Relationships to Disclose